End-of-day quote
Shanghai S.E.
06:00:00 2024-05-08 pm EDT
|
5-day change
|
1st Jan Change
|
547.8
CNY
|
+2.57%
|
|
+8.75%
|
+40.99%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18,668
|
20,463
|
25,854
|
36,453
|
-
|
-
|
Enterprise Value (EV)
1 |
18,668
|
20,463
|
25,854
|
36,453
|
36,453
|
36,453
|
P/E ratio
|
88.3
x
|
57.9
x
|
49.1
x
|
55.7
x
|
40.7
x
|
32.9
x
|
Yield
|
0.36%
|
0.54%
|
0.51%
|
0.49%
|
0.71%
|
-
|
Capitalization / Revenue
|
22.5
x
|
16.8
x
|
15.7
x
|
16.6
x
|
12.4
x
|
9.65
x
|
EV / Revenue
|
22.5
x
|
16.8
x
|
15.7
x
|
16.6
x
|
12.4
x
|
9.65
x
|
EV / EBITDA
|
74.2
x
|
46.4
x
|
39.2
x
|
41.7
x
|
31.3
x
|
24.7
x
|
EV / FCF
|
1,328,964,108
x
|
91,157,838
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
10.5
x
|
11.6
x
|
13.6
x
|
15.4
x
|
11.1
x
|
9.25
x
|
Nbr of stocks (in thousands)
|
66,670
|
66,670
|
66,550
|
66,550
|
-
|
-
|
Reference price
2 |
280.0
|
306.9
|
388.5
|
547.8
|
547.8
|
547.8
|
Announcement Date
|
2/24/22
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
479.4
|
828.7
|
1,216
|
1,650
|
2,196
|
2,948
|
3,776
|
EBITDA
1 |
-
|
251.4
|
440.9
|
659.5
|
874.8
|
1,165
|
1,473
|
EBIT
1 |
119.4
|
222.5
|
397
|
600.4
|
779.4
|
1,066
|
1,375
|
Operating Margin
|
24.91%
|
26.85%
|
32.65%
|
36.38%
|
35.5%
|
36.16%
|
36.41%
|
Earnings before Tax (EBT)
1 |
121.2
|
221.6
|
395.1
|
596.4
|
779.9
|
1,066
|
1,374
|
Net income
1 |
110.8
|
207.9
|
358
|
533.9
|
703.5
|
947.2
|
1,240
|
Net margin
|
23.11%
|
25.09%
|
29.44%
|
32.35%
|
32.04%
|
32.13%
|
32.83%
|
EPS
2 |
2.220
|
3.170
|
5.300
|
7.920
|
9.840
|
13.46
|
16.63
|
Free Cash Flow
|
-
|
14.05
|
224.5
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
1.7%
|
18.46%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
5.59%
|
50.91%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
6.76%
|
62.7%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
1.000
|
1.650
|
2.000
|
2.700
|
3.885
|
-
|
Announcement Date
|
2/24/21
|
2/24/22
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
14
|
224
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
27.4%
|
18.4%
|
20.1%
|
30.2%
|
28.6%
|
29.4%
|
28.3%
|
ROA (Net income/ Total Assets)
|
-
|
15.9%
|
16.9%
|
22.2%
|
21.3%
|
22.8%
|
19.6%
|
Assets
1 |
-
|
1,309
|
2,120
|
2,404
|
3,303
|
4,159
|
6,326
|
Book Value Per Share
2 |
9.210
|
26.70
|
26.40
|
28.50
|
35.60
|
49.20
|
59.20
|
Cash Flow per Share
2 |
2.960
|
2.770
|
5.510
|
10.30
|
9.850
|
16.60
|
12.50
|
Capex
1 |
-
|
167
|
143
|
189
|
125
|
168
|
135
|
Capex / Sales
|
-
|
20.19%
|
11.76%
|
11.48%
|
5.69%
|
5.71%
|
3.57%
|
Announcement Date
|
2/24/21
|
2/24/22
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
547.8
CNY Average target price
497.1
CNY Spread / Average Target -9.24% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.99% | 5.05B | | +73.46% | 12.41B | | -16.75% | 8.12B | | +5.93% | 6.59B | | -6.42% | 5.83B | | +13.79% | 5.46B | | -19.05% | 4.02B | | -34.55% | 2.47B | | -1.49% | 2.02B | | +4.94% | 1.89B |
Medical Equipment
|